On Jan. 28, 2022, Novavax and Israel’s Ministry of Health announced an agreement for the purchase of NVX-CoV2373, the company’s recombinant nanoparticle protein-based COVID-19 vaccine candidate with Matrix-M adjuvant.

Under the advance purchase agreement, Novavax provided an initial 5 million doses of its protein-based vaccine with an option for Israel to purchase an additional 5 million doses.